Biotechnology

Erasca

Erasca Showcases Cancer Drug Pipeline, ERAS-0015 Clinical Data Promising with Financial Stability to 2028

Erasca Presents Early Clinical Data for ERAS-0015, NSCLC Response Rate 62%-75%

Erasca released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6027 (forecast USD -0.2115)

Erasca Reports Q1 Net Loss and Operating Profit

Erasca Announces Positive Phase 1 Clinical Trial Results for RAS Drug ERAS-0015

Erasca Schedules Conference Call to Discuss Preliminary Dose Escalation Results for ERAS-0015

Erasca Updates Data Release Timeline for ERAS-0015

Erasca Completes HERKULES-3 Trial

Erasca released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1024 (forecast USD -0.1067)

Erasca released FY2025 Annual Earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4392 (forecast USD -0.4441)

Erasca Inc. Released Corporate Presentation on R&D Pipeline and Financing Status

Erasca Extends ERAS-0015 License in China

Erasca Inc. Secures Patent for Full KRAS Inhibitor ERAS-4001

Erasca Executives Discuss Clinical Data and R&D Pipeline of ERAS-0015

Erasca Inc. CFO and CBO David M. Chacko Buys Company's Common Stock

Erasca (ERAS) Files for a $150 Million IPO and Offers Over-Allotment Option to Underwriters

Erasca Reports Total Cash and Equivalents of Approximately $341.8 Million

HC Wainwright Upgrades Erasca's 2027 Fiscal Year Profit Forecast and Maintains Buy Rating

HC Wainwright Raises Erasca's Target Price to $11

Erasca Announces Cancer Elimination Strategy, Focusing on RAS/MAPK Pathway

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ERAS

RVMD

SBIO

ARKG

LABU

Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) regarding possible violations of federal securities laws following a patent infringement allegation from Revolution Medicines. This news caused Erasca's stock to drop by approximately 48%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Revolution Medicines

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

Erasca (NASDAQ:ERAS) executives presented promising early clinical data for ERAS-0015, a RAS-targeting drug, at a Bank of America conference. They reported response rates of 62%-75% in non-small cell lung cancer and discussed plans for FDA discussions on accelerated approval. The company is also exploring combination therapies with pembrolizumab and has seen a 41% response rate in pancreatic cancer. Erasca received a patent for ERAS-0015, extending protection to 2043.

Market Beat

iShares US Pharma

Health Care Select Sector SPDR

VG Health

Bank of America

Merck

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference

J.P. Morgan analyst Anupam Rama has maintained a Buy rating on Erasca (ERAS) with a price target of $23.00, while the stock closed at $10.46. Rama has an average return of 23.7% and a success rate of 52.03% on his recommendations. Mizuho Securities also issued a Buy rating for Erasca, but Bank of America Securities reiterated a Sell rating on the same day.

Tip Ranks

iShares Global Healthcare

JPMorgan Chase

Sarepta Therap

Travere Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

Earnings Watch

Erasca | 10-Q: FY2026 Q1 Revenue: USD 0

Erasca | 8-K: FY2026 Q1 Revenue: USD 0

MRNA

SNDA

Healthcare stocks declined late Monday, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF down 0.4%. Zoetis shares fell 7.5% after a price target cut by BNP Paribas. Moderna shares dropped 3.7% amid news of early-stage vaccine development. Sonida Senior Living reported a Q1 loss of $2.39 per share, leading to a 3.3% decline in shares. In contrast, Erasca shares rose 3% following a collaboration with Merck for a clinical trial.

Fidelity

Moderna

Zoetis

Sonida Senior Living

BNP Paribas

Factset Research

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks showed mixed performance on May 11, 2026, with the NYSE Healthcare Index up 0.2%. Moderna's shares fell 2.2% as it works on early-stage hantavirus vaccines. Sonida Senior Living reported a Q1 loss of $2.39 per share, leading to a 3.6% drop in its stock. In contrast, Erasca's shares rose 3.3% after announcing a collaboration with Merck for a clinical trial, while Merck's stock increased by 1.2%.

Erasca(ERAS.US)